Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
- Conditions
- Oral Chronic Graft-versus-host Disease
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT00686855
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT00679367
- Locations
- 🇺🇸
Boston University Cancer Research Center, Boston, Massachusetts, United States
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 220
- Registration Number
- NCT00671658
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic LeukemiaChildhood B Acute Lymphoblastic Leukemia
- Interventions
- Drug: Calaspargase Pegol-mknlDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoneRadiation: Radiation TherapyDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 166
- Registration Number
- NCT00671034
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸University of Connecticut, Farmington, Connecticut, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
- Conditions
- Burkitt's LymphomaBurkitt'S-like Lymphoma
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT00669877
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
- Conditions
- Arthritis, Gouty
- Interventions
- Biological: canakinumabDrug: dexamethasoneOther: placebo matching dexamethasoneOther: placebo matching canakinumab
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 6
- Registration Number
- NCT00663169
- Locations
- 🇬🇧
Novartis Investigator Site, Glasgow, United Kingdom
Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura
- Conditions
- Nonneoplastic Condition
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2017-02-20
- Target Recruit Count
- 150
- Registration Number
- NCT00657410
- Locations
- 🇮🇹
S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹USL 8 - Ospedale S.Donato, Arezzo, Italy
🇮🇹UO Ematologia con trapianto- AOU Policlinico Consorziale di Bari, Bari, Italy
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
- Conditions
- DS Stage III Multiple MyelomaDS Stage I Multiple MyelomaDS Stage II Multiple Myeloma
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 525
- Registration Number
- NCT00644228
- Locations
- 🇺🇸
Good Samaritan Hospital - Dayton, Dayton, Ohio, United States
🇺🇸Miami Valley Hospital, Dayton, Ohio, United States
🇺🇸Miami Valley Hospital North, Dayton, Ohio, United States
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00642954
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: sargramostimDrug: busulfanDrug: cyclophosphamideDrug: dexamethasoneDrug: etoposideProcedure: bone marrow transplantationProcedure: hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT00630565
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.